Back to search

National and Kapodistrian University of Athens

Η ανοσοϊστοχημική μελέτη των ανδρογονικών αποδοχέων (AR) και της ενζυμικής αρωματάσης (P450 AROM), σε ασθενείς με καρκίνο μαστού βασικού τύπου (Basal Like Breast Cancer) και τριπλή αρνητική έκφραση, ανοσοϋποδοχέων: ER/PGR/HER2 (Triple Negative Breast Cancer Tumors): εργαστηριακή διερεύνηση και κλινική-θεραπευτική συσχέτιση

Abstract

dc:description

In light of the controversial published literature, this thesis aims to examine the potential prognostic role of androgen receptor (AR) immunohistochemical expression in triple negative breast cancer (TNBC). Ninety patients with TNBC were included in this thesis; the associations between AR expression (Allred score), clinicopathological variables (stage, grade, histological subtype, tumor size, nodal status, age at diagnosis, Ki67 expression, and p53 expression), and overall survival were evaluated. The study showed that AR expression was not associated with stage, grade, histological subtype, tumor size, nodal status, age at diagnosis, Ki67 expression, and p53 expression. AR immunopositivity was not associated with overall survival either at the univariate or at the multivariate Cox regression analysis (multivariate hazard ratio =0.66, 95% confidence interval: 0.26-1.70, P=0.393). In conclusion, AR expression does not seem to play a prognostic role in TNBC.

Degree

thesis:*
Grantor dc:publisher
National and Kapodistrian University of Athens
Year dc:date
2018

Author and committee

dc:creator, dc:contributor.*
Authors dc:creator
  • Giannos, Argyrios
  • Γιάννος, Αργύριος

Subjects

dc:subject × 10

Rights

Language dc:language
gre

Identifiers

dc:identifier.*
Identifier
10.12681/eadd/42919

Chain of custody

source
Harvested from
Greek National Archive of PhD Theses
Base URL
phdtheses.ekt.gr/eadd_oai/request
Last updated
2026-11-18
Source record
OAI-PMH GetRecord
citation

Giannos, Argyrios; Γιάννος, Αργύριος. Η ανοσοϊστοχημική μελέτη των ανδρογονικών αποδοχέων (AR) και της ενζυμικής αρωματάσης (P450 AROM), σε ασθενείς με καρκίνο μαστού βασικού τύπου (Basal Like Breast Cancer) και τριπλή αρνητική έκφραση, ανοσοϋποδοχέων: ER/PGR/HER2 (Triple Negative Breast Cancer Tumors): εργαστηριακή διερεύνηση και κλινική-θεραπευτική συσχέτιση. National and Kapodistrian University of Athens, 2018. http://hdl.handle.net/10442/hedi/42919